Survival after surgery in stage IA and IB non-small cell lung cancer

American Journal of Respiratory and Critical Care Medicine

Volumn 177, Issue 5, 2008, Pages 516-523

  Ost, David ^a,b   Goldberg, Judith ^a   Rolnitzky, Linda ^a   Rom, William N ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HCC   (United States)

Author keywords

Adenocarcinoma; Lung cancer; Lung cancer epidemiology; Lung cancer staging

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; LOBECTOMY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; CANCER REGISTRY; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; TUMOR RECURRENCE;

ADENOCARCINOMA; AGED; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SEER PROGRAM;

EID: 40649124523     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200706-815OC     Document Type: Article

References (21)

1. Scagliotti GV, Fossati R, Torri V, Crino L, Giaccone G, Silvano G, Martelli M, Clerici M, Cognetti F, Tonato M. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003;95:1453-1461.
2. Waller D, Peake MD, Stephens RJ, Gower NH, Milroy R, Parmar MK, Rudd RM, Spiro SG. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004;26:173-182.
3. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
4. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, et al; J.B.R.T.I.; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597.
5. Blum RH. Adjuvant chemotherapy for lung cancer: a new standard of care. N Engl J Med 2004;350:404-405.
6. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N, et al; the Japan Lung Cancer Research Group on Postsurgical Adjuvant. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713-1721.
7. Pisters KMW. Adjuvant chemotherapy for non-small-cell lung cancer: the smoke clears. N Engl J Med 2005;352:2640-2642.
8. Ost D. Prediction models for recurrence and survival following surgery for stage IA and IB non-small cell lung cancer. Chest 2006;130:102S.
9. Surveillance, Epidemiology, and End Results (SEER) Program Populations (1969-2004). Bethesda (MD):National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; 2007.
10. Allison PD. Survival analysis using SAS: a practical guide. Cary, NC: SAS Institute, Inc.; 1995.
11. Raumlau-Hansen H. Smoothing counting process intensities by means of kernel functions. Annals of Statistics 1983;11:453-466.
12. Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brooks BJ, Perry MC, Livingston RB, Johnson DH. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 2000;343:1217-1222.
13. Mountain CF, Lukeman JM, Hammar SP, Chamberlain DW, Coulson WF, Page DL, Victor TA, Weiland LH. Lung cancer classification: the relationship of disease extent and cell type to survival in a clinical trials population. J Surg Oncol 1987;35:147-156.
14. Hamada C, Tanaka F, Ohta M, Fujimura S, Kodama K, Imaizumi M, Wada H. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 2005;23:4999-5006.
15. Greenberg AK, Lee MS. Biomarkers for lung cancer: clinical uses. Curr Opin Pulm Med 2007;13:249-255.
16. Kulpa J, Wojcik E, Reinfuss M, Kolodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 2002;48:1931-1937.
17. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356:11-20.
18. Kim JS, Kim JW, Han J, Shim YM, Park J, Kim DH. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Res 2006;66:4049-4054.
19. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-991.
20. Papi A, Casoni G, Caramori G, Guzzinati I, Boschetto P, Ravenna F, Calia N, Petruzzelli S, Corbetta L, Cavallesco G, et al. COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma. Thorax 2004;59:679-681.
21. Wang SY, Hu YL, Wu YL, Li X, Chi GB, Chen Y, Dai WS. A comparative study of the risk factors for lung cancer in Guangdong, China. Lung Cancer 1996;14:S99-S105.